N
17.22
-0.54 (-3.04%)
| Previous Close | 17.76 |
| Open | 17.73 |
| Volume | 91,079 |
| Avg. Volume (3M) | 266,208 |
| Market Cap | 245,593,360 |
| Price / Sales | 438.73 |
| Price / Book | 0.990 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -9,701.19% |
| Diluted EPS (TTM) | -4.36 |
| Total Debt/Equity (MRQ) | 4.01% |
| Current Ratio (MRQ) | 21.03 |
| Operating Cash Flow (TTM) | -69.73 M |
| Levered Free Cash Flow (TTM) | -40.39 M |
| Return on Assets (TTM) | -21.97% |
| Return on Equity (TTM) | -34.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Neurogene Inc. | Bearish | Bearish |
AIStockmoo Score
-1.9
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.88 |
|
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today’s complex devastating neurological diseases into treatable conditions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 9.28% |
| % Held by Institutions | 115.82% |
| 52 Weeks Range | ||
| Median | 50.00 (190.36%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 17 Jun 2025 | 50.00 (190.36%) | Buy | 18.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Sep 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11 Aug 2025 | Announcement | Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates |
| 08 Aug 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 03 Jul 2025 | Announcement | Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 30 Jun 2025 | Announcement | Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |